You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 2019010
Jan 2020042
Feb 2020042
Mar 2020001
May 2020052
Jun 2020082
Jul 2020061
Aug 2020021
Sep 2020063
Oct 2020042
Nov 2020032
Dec 2020012
Jan 2021021
Feb 2021002
Mar 2021002
Apr 2021032
May 2021033
Jun 2021013
Jul 2021042
Aug 2021016
Sep 2021053
Oct 20210313
Nov 2021049
Dec 2021081
Jan 2022062
Feb 2022020
Mar 2022064
Apr 2022030
May 2022079
Jun 2022045
Jul 2022051
Aug 2022041
Sep 2022049
Oct 2022062
Nov 2022091
Dec 2022061
Jan 2023093
Feb 2023010
Mar 2023021
Apr 2023020
May 2023031
Jun 2023010
Jul 2023055
Aug 2023011
Sep 2023040
Oct 2023021
Nov 2023062
Dec 2023051
Jan 20240103
Feb 2024060
Mar 2024031
Apr 2024032
May 2024051
Jun 2024061
Jul 2024063
Aug 2024051
Sep 2024054
Oct 2024085
Nov 20240153
Dec 2024073
Jan 2025096
Feb 2025084
Mar 20250810
Apr 20250143
May 2025065
Jun 20250112
Total0316174